Moreover, a similar expression analysis is described in Figure 6, regarding the treatment of the same tested human ovarian cancer lines with a 3-AB agent in combination with ASA-A, ASA-B or ASA-C, enclosing the respective alterations on the relative PARP1/ACTB mRNA cellular content. This evidence concerns the gene PARP1 and ovarian carcinoma.